Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease

Launched by AIN SHAMS UNIVERSITY · Dec 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how effective different biological therapies are in helping children and young adults with Inflammatory Bowel Disease (IBD) achieve remission, which means reducing or eliminating symptoms and inflammation. The trial aims to compare the effects of these medications by looking at clinical signs, lab tests, and tissue samples.

The study is looking for participants aged between 30 days and 18 years who have been diagnosed with IBD and are experiencing severe symptoms or a relapse. To be eligible, they need to meet specific medical criteria that include both clinical and laboratory results. However, children who are already stable on biological therapy or have certain immune system issues will not be included. While the trial is not yet recruiting participants, those who join can expect to be closely monitored during the treatment process to see how well these therapies work for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients fulfilling modified Porto criteria for diagnosis of IBD including clinical features, laboratory, radiological and pathological findings.
• • Patients initially severely diseased or in relapse and planned to start or change biological therapy.
• Exclusion Criteria:
• • Patients already on biological therapy and controlled. Patients with known humeral or cell mediated immunodeficiency.
• • Ethical